Ravi Agrawal, a promoter of Ajanta Pharma Limited, has announced the release of a pledge on a total of 54,796 equity shares. This action, effective on August 6, 2026, through August 12, 2026, was attributed to ‘Excess Pledge’. The disclosure provides transparency on shareholding dynamics for investors.
Promoter Pledge Release
Ravi Agrawal, acting as a promoter of Ajanta Pharma Limited and through the Trustee Ravi Agrawal Trust, has officially disclosed the release of a pledge on a significant block of shares. The total number of equity shares affected by this release is 54,796. This move signifies a reduction in the encumbered shares held by the promoter group.
Details of Share Release
The announcement, dated August 14, 2026, details several instances of pledge release. Specifically, Ravi P. Agrawal, trustee for Ravi Agrawal Trust, saw a release of 1,534,966 shares on August 6, 2026, due to ‘Excess Pledge’. Further releases by the same trust included 1,506,600 shares on August 7, 2026, 1,482,800 shares on August 11, 2026, and 1,481,500 shares on August 12, 2026, all attributed to ‘Excess Pledge’ and for Business Financing purposes.
The reason cited for these releases is ‘Excess Pledge’, indicating that the outstanding pledged shares exceeded a certain threshold. These disclosures are made in compliance with the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, providing stakeholders with crucial information regarding the promoter’s shareholding status.
Source: BSE
